Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

LEXICON PHARMACEUTICALS INC (LXRX)

134 + Investors. Track Smart Money conviction in LXRX. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -3
Streak
1Q ▼
Buyers last Q
44%

Smart Money Signals — LXRX

Based on 119 hedge funds · latest filing: 2025 Q4 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their LXRX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
📊

High ownership — 89% of 3.0Y peak

89% of all-time peak
119 funds currently hold this stock — 89% of the 3.0-year high of 133 funds (reached 2024 Q3). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
📉

Outflows — 6% fewer funds vs a year ago

fund count last 6Q
7 fewer hedge funds hold LXRX compared to a year ago (-6% decline). When institutions consistently reduce their exposure, it's worth exploring the underlying fundamental reasons driving them away.
🟠

More sellers than buyers — 44% buying

50 buying64 selling
Last quarter: 64 funds reduced or exited vs 50 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.
➡️

Steady new buyers — ~19 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 32 → 27 → 21 → 19. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔒

56% of holders stayed for 2+ years

■ 56% conviction (2yr+) ■ 23% medium ■ 21% new
67 out of 119 hedge funds have held LXRX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
📊

Peak discovery — momentum slowing

26 → 32 → 27 → 21 → 19 new funds/Q
New funds entering each quarter: 32 → 27 → 21 → 19. LXRX is well-known in the hedge fund world, but fresh entries are gradually declining. The explosive phase of institutional discovery is likely behind us.
🏛️

Deep conviction — 60% of holders stayed 2+ years

■ 60% veterans ■ 13% 1-2yr ■ 27% new
Of 124 current holders: 74 (60%) have held for over 2 years without selling. These are not momentum buyers — they have lived through drawdowns and stayed. A large veteran base acts as a stabilizing force during selloffs.
✅

Strong quality — 26% AUM from major funds

26% from top-100 AUM funds
31 of 119 holders rank in the top 100 by AUM, accounting for 26% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
3.3
out of 10
Low Exit Risk
Exit risk score 3.3/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — LXRX

In 2025 Q4, 50 hedge funds were net buyers of LXRX (19 opened a new position, 31 added to an existing one), while 64 reduced or exited (42 trimmed, 22 sold completely) — a 44% buyer ratio, indicating roughly balanced activity. 26% of total institutional value in LXRX is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: -3 funds (more exits than new entries). Total institutional holders: 119.

Hedge Fund Ownership: LXRX

How many hedge funds hold LXRX — quarterly history vs. share price
Quarterly hedge fund ownership of LXRX vs. share price

Market Analysis: LXRX

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: LXRX

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy LEXICON PHARMACEUTICALS INC (LXRX) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much LXRX has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 51d ago
LXRX
+42.3%
XLV
+0.4%

LXRX outperformed XLV by +41.9% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 6d ago
LXRX
-0.9%
XLV
+1.4%

Since the filing became public, LXRX outperformed XLV by -2.3% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

11 top-rated funds 0 high-conviction
Consensus
4.7
/ 10
breadth
×
Elite
1.1
/ 10
conviction
Hedge Fund Positioning: LXRX
134 + Investors

Track Smart Money conviction in LXRX. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 134 119 12.61%
13F Shares 325M 261M 24.44%
Total Value $505M $301M 68.05%
New Positions 31 19 +12
Increased Positions 39 30 +9
Closed Positions 16 22 -6
Reduced Positions 28 40 -12
Total Calls 3 3 -
Total Puts 3 2 50.0%
PUT/CALL Ratio 1.0 0.67 Neutral

Statistics: LXRX

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

134 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in LXRX. Verified SEC 13F-HR filings.

QUARTER:
Top 25 institutional holders of LXRX — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Artal Group S.A. 23.89% 154,734,327 $241.4M
2 Siren, L.L.C. 1.92% 44,303,518 $69.1M
3 Ishara Investments LP 1.33% 902,000 $1.4M
4 Sessa Capital IM, L.P. 0.51% 17,912,961 $27.9M
5 Quantessence Capital LLC 0.14% 18,581 $29K
6 GSA CAPITAL PARTNERS LLP 0.09% 930,089 $1K
7 ADAR1 Capital Management, LLC 0.07% 750,000 $1.2M
8 R Squared Ltd 0.06% 67,526 $105K
9 Catalyst Funds Management Pty Ltd 0.05% 207,900 $324K
10 Hennion & Walsh Asset Management, Inc. 0.04% 848,138 $1.3M
11 Headlands Technologies LLC 0.03% 191,322 $298K
12 TANG CAPITAL MANAGEMENT LLC 0.03% 399,700 $624K
13 Quarry LP 0.03% 110,000 $172K
14 DIKER MANAGEMENT LLC 0.03% 20,000 $31K
15 Diametric Capital, LP 0.03% 67,841 $106K
16 Straight Path Wealth Management 0.03% 62,666 $98K
17 SECURITY NATIONAL BANK OF SIOUX CITY IOWA /IA/ 0.02% 26,650 $42K
18 EntryPoint Capital, LLC 0.02% 48,498 $76K
19 Ikarian Capital, LLC 0.02% 164,674 $257K
20 Invera Wealth Advisors, LLC 0.02% 20,000 $31K
21 Point72 Asset Management, L.P. 0.02% 7,814,606 $12.2M
22 Fortis Group Advisors, LLC 0.01% 50,000 $80K
23 Talisman Wealth Advisors LLC 0.01% 10,000 $16K
24 Bridgewater Advisors Inc. 0.01% 82,209 $201K
25 Compagnie Lombard Odier SCmA 0.01% 510,000 $796K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — LEXICON PHARMACEUTICALS INC (LXRX)

What does the Smart Money Trend signal show for LXRX?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their LXRX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for LXRX?

More sellers than buyers — 44% buying: Last quarter: 64 funds reduced or exited vs 50 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

What is the fund quality score for LXRX holders?

Strong quality — 26% AUM from major funds: 31 of 119 holders rank in the top 100 by AUM, accounting for 26% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held LXRX?

56% of holders stayed for 2+ years: 67 out of 119 hedge funds have held LXRX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy LEXICON PHARMACEUTICALS INC (LXRX) following the 2026 Q1 hedge fund 13F filings?

As of today, LXRX has moved -0.9% since the 2026 Q1 13F filing date (May 15, 2026), compared to +1.4% for the XLV sector ETF — an outperformance of -2.3%. Since the quarter end (March 31, 2026), LXRX has gained +42.3% vs +0.4% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →